+971 56 274 1787WhatsApp
Symptom

Health Information

Comprehensive undefined information and treatment options at Healers Clinic Dubai.

"You are not alone in this journey."

15,000+ Patients
DHA Licensed
95% Success Rate
27+ Years
Expert Definition

Understanding This Symptom

Medical Definition

Subject Matter Expert Verified

Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by autoantibodies attacking components of the neuromuscular junction, most commonly the acetylcholine receptors (AChR antibodies) on skeletal muscle cells.

This antibody-mediated attack disrupts normal nerve-to-muscle communication, causing fluctuating muscle weakness that worsens with activity and improves with rest.

The condition affects voluntary muscles, particularly those controlling eye movements (causing ptosis and diplopia), facial expressions, swallowing (bulbar weakness), speech, and breathing.

Affects approximately 20 per 100,000 people globally, with women typically developing MG earlier (20s-30s) and men later (60s-70s).

Quick Facts

Expert-reviewed by medical professionals
Based on current medical research
Updated for 2026 standards

Need More Information?

Our experts can provide personalized guidance

Book Consultation
Healthy State

What Optimal Health Looks Like

Understanding how your body functions when healthy helps identify dysfunction

In a healthy neuromuscular system, motor neurons transmit signals to skeletal muscles through the neuromuscular junction.

When a nerve impulse arrives at the nerve terminal, it triggers the release of acetylcholine (ACh) into the synaptic cleft.

Acetylcholine binds to nicotinic acetylcholine receptors (AChR) on the muscle membrane, causing sodium channels to open and depolarizing the muscle fiber.

This generates an action potential that initiates muscle contraction.

Healthy Function

Your body is designed to maintain balance and self-regulate

Optimal Range
Development Process

How This Develops

1

Autoantibody production - In

2

Complement-mediated damage - AChR antibodies activate the classical complement pathway, leading to membrane attack complex (MAC) formation that destroys the postsynaptic membrane folds and reduces receptor density by

3

Receptor blockade - Antibodies physically block the binding sites where acetylcholine normally attaches, preventing normal nerve signal transmission

4

Receptor modulation - Antibody cross-linking accelerates AChR internalization and degradation, further reducing receptor numbers

5

In anti-MuSK MG (

6

In anti-LRP

7

Thymic abnormalities -

8

Presynaptic dysfunction - Some antibodies may affect voltage-gated calcium channels, further impairing acetylcholine release

9

Fatigue mechanism - With repeated stimulation, the limited remaining receptors cannot sustain adequate depolarization, causing progressive weakness with activity that improves with rest

10

Myasthenic crisis - Severe disease can cause respiratory muscle failure requiring mechanical ventilation, triggered by infection, surgery, medication, or stress

Understanding the mechanism helps us target the root cause rather than just treating symptoms.

Cost of Waiting

What Happens If Left Untreated

Understanding the consequences helps you make informed decisions about your health

Short-Term Consequences

Days to weeks

  • [object Object] | [object Object] | [object Object]

Time Matters

Don't wait for symptoms to worsen. Early intervention leads to better outcomes.

Common Questions

Frequently Asked Questions

Expertise Behind This Guide

Evidence-Based Information

Dr. Hafeel Afsar, DHA Licensed Integrative Medicine

References & Further Reading

Gilhus NE, Verschuuren JJ. Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies. Lancet Neurol. 2015;14(10):1023-1036. PMID: 26376969 - Comprehensive review of MG subtypes and treatment approaches.
Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016;375(6):511-522. PMID: 27509100 - MGTX trial demonstrating thymectomy benefit in non-thymomatous MG.
Sanders DB, Wolfe GI, Benatar M, et al. International Consensus Guidance for Management of Myasthenia Gravis. Neurology. 2016;87(4):419-425. PMID: 27358333 - International consensus guidelines for MG diagnosis and treatment.
Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia Gravis: Past, Present, and Future. J Clin Invest. 2006;116(11):2843-2854. PMID: 17080188 - Comprehensive review of MG pathophysiology and autoantibodies.
Carr AS, Cardwell CR, McCarron PO, McConville J. A Systematic Review of Population Based Epidemiological Studies in Myasthenia Gravis. BMC Neurol. 2010;10:46. PMID: 20507633 - Epidemiological data on MG prevalence and demographics.
Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia Gravis: Recommendations for Clinical Research Standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16-23. PMID: 10891897 - Standardized definitions and outcome measures for MG.
Silvestri NJ, Wolfe GI. Myasthenia Gravis. Semin Neurol. 2012;32(3):215-226. PMID: 23117942 - Clinical review of MG diagnosis and management.
Guptill JT, Sanders DB, Evoli A. Anti-MuSK Antibody Myasthenia Gravis: Clinical Findings and Response to Treatment in Two Large Cohorts. Muscle Nerve. 2011;44(1):36-40. PMID: 21607984 - Characteristics and treatment of MuSK-positive MG.
Suh J, Goldstein JM, Nowak RJ. Clinical Characteristics of Refractory Myasthenia Gravis Patients. Yale J Biol Med. 2013;86(3):255-260. PMID: 24058312 - Features and management of refractory MG.
Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic Crisis: Clinical Features, Mortality, Complications, and Risk Factors for Prolonged Intubation. Neurology. 1997;48(5):1253-1260. PMID: 9153442 - Analysis of myasthenic crisis outcomes and risk factors.

This information is for educational purposes and not a substitute for professional medical advice.